Stay updated with breaking news from Abbvie Stemcentrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.
24.03.2022 - - Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid ...
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in... | March 24, 2022